Basal Insulin Market, By Type (Glargine, Detemir, Degludec), By Delivery Device (Syringes, Pens, Pumps, and Others), By Indication (Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Nov 2023

Code : CMI6272

Pages :160

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Recent Developments:

New product launches:

In March 2023, Eli Lilly and Company, a U.S.-based pharmaceutical company, announced its plans to launch Rezvoglar, an interchangeable insulin glargine biosimilar, at a 78% discount to the originator (Lantus). In November 2022, Rezvolgar (insuling glargine-aglr) became the fourth biosimilar to be authorized and given an interchangeability designation.
In November 2021, Viatris Inc., a global healthcare company, and Biocon Biologics Ltd., a subsidiary of Biocon, announced the launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine injection, an unbranded product, in the U.S. to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.
In September 2022, Novo Nordisk Inc., a global biopharmaceutical company, announced the launch of Tresiba (insulin degludec) injection, a long-acting, once-daily basal insulin intended to treat high blood sugar in diabetics aged 1 year or older

Acquisitions and partnerships:

In September 2023, Biocon Biologics Ltd., announced that the company has completed the integration of the acquired biosimilars business from Viatris, a worldwide pharmaceutical and healthcare organization in North America, which includes insulin biosimilars such as Semglee (Insulin Glargine)
In May 2023, Medtronic plc, a healthcare technology company, announced that it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd., a manufacturer of the EOPatch device, a tubeless, wearable and fully disposable insulin delivery device
In October 2022, PureHealth, a U.A.E.-based medical devices company, announced the launch of the first factory in the Middle East to produce Glargine (the first long-acting biological alternative to insulin) for the treatment of diabetes in partnership with Gulf Pharmaceutical Industries Company (Julphar), one of the leading pharmaceutical companies in the U.A.E.